United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $263.97, for a total value of $2,111,760.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $34,316.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Stock Up 0.4 %
Shares of NASDAQ UTHR opened at $265.59 on Tuesday. United Therapeutics Co. has a one year low of $158.38 and a one year high of $270.61. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The business’s fifty day moving average price is $228.55 and its 200-day moving average price is $224.37. The stock has a market capitalization of $12.10 billion, a PE ratio of 18.07, a P/E/G ratio of 1.77 and a beta of 0.59.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the company. Bank of America reiterated an “underperform” rating on shares of United Therapeutics in a report on Tuesday, September 20th. Wedbush upped their price objective on United Therapeutics from $250.00 to $305.00 in a research note on Thursday, November 3rd. Oppenheimer upped their price objective on United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, November 3rd. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $282.75.
Institutional Inflows and Outflows
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.